

Ref: FOI/GS/ID 6359

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: mtw-tr.foiadmin@nhs.net

30 November 2020

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Head and neck cancer (squamous cell carcinoma).

*You asked:*

- 1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma)? Of these patients, how many are locally advanced, recurrent and/or metastatic?*
  - a. Total squamous cell carcinoma*
  - b. Locally advanced*
  - c. Recurrent and/or metastatic*
- 2. For the metastatic head and neck cancer patients treated in the past 3 months, could you specify (if possible) how many received first-line treatment versus second-line treatment?*
- 3. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?*
  - a. Carboplatin (monotherapy or in combination with 5-FU)*
  - b. Cisplatin (monotherapy or in combination with 5-FU)*
  - c. Cetuximab with/without chemotherapy*
  - d. Cetuximab with radiotherapy*
  - e. Pembrolizumab monotherapy*
  - f. Pembrolizumab with chemotherapy*
  - g. Nivolumab*
  - h. Docetaxel (monotherapy or in combination with 5-FU)*
  - i. Fluorouracil (5FU)*
  - j. Radiotherapy only*
  - k. Other*
- 4. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:*

- a. Sunitinib
- b. Avelumab + Axitinib
- c. Axinitib
- d. Cabozantinib
- e. Everolimus
- f. Lenvantinib + Everolimus
- g. Nivolumab
- h. Nivolumab + Ipilimumab
- i. Pazopanib
- j. Pembrolizumab + Axitinib
- k. Sunitinib
- l. Temsirolimus
- m. Tivozanib
- n. Other

5. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

6. Does your trust participate in any ongoing clinical trials for the treatment of renal cell carcinoma? If so, can you please provide the name of each trial along with the number of patients taking part?

Trust response:

- 1.
- a. 21
- b. On the assumption that it is a high T or N score, then 2
- 2. None
- 3.
- g. 2 patients
- j. 14 patients
- k. 1 patient having Paclitaxel and 1 patient having Zoledronic Acid as a supportive treatment)
- 4. No patients with RCC had Chemo treatment at the Trust in the period
- 5. The only head and neck cancer trial we are currently recruiting to is: BRITER Study (Brain Imaging to predict Toxicity in Elderly patients after Radiotherapy)

IRAS no: 216343

IRAS category: Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative methodology

There are 7 patients recruited to it

6. There are currently no renal cell cancer trials running.